𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy of Equoral in Prophylactic Immunosuppression after De Novo Kidney Transplantation

✍ Scribed by Josef Zadražil; Sadek Al Jabry; Pavel Horák; Petr Bachleda; Agata Gibejová; Vojtěch Kamarád

Publisher
Wiley (John Wiley & Sons)
Year
2007
Tongue
English
Weight
55 KB
Volume
36
Category
Article
ISSN
0090-2934

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

De novo renal cell carcinoma of native k
De novo renal cell carcinoma of native kidney in renal transplant recipients
✍ Yann Neuzillet; Franck Lay; Aline Luccioni; Laurent Daniel; Yvon Berland; Christ 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## BACKGROUND The 10‐year risk of developing a solid malignancy is 20% for kidney transplant recipients. The goal of the current study was to investigate the epidemiology and the diagnostic and prognostic parameters associated with de novo malignancies of the native kidney among transp

The efficacy of prophylactic interferon
The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation
✍ Patricia A. Sheiner; Peter Boros; Franklin M. Klion; Swan N. Thung; Leona Kim Sc 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 2 views

Clinical recurrence of hepatitis C after liver transplantation can lead to cirrhosis, liver failure, and death. In patients undergoing liver transplantation for hepatitis C, we assessed the efficacy of interferon alfa-2b (IFN) in preventing recurrent hepatitis. We randomized 86 patients to either an

Safety, tolerability, and efficacy of ev
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results
✍ Gary Levy; Heinz Schmidli; Jeffrey Punch; Elizabeth Tuttle-Newhall; David Mayer; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

Everolimus is a macrolide immunosuppressive agent with known consistent absorption. In this double-blind study, we examined the safety and tolerability of everolimus vs. placebo in de novo liver transplant recipients. One hundred and nineteen liver allograft recipients were randomized to 1 of 4 grou

Development of pulmonary hypertension in
Development of pulmonary hypertension in 5 patients after pediatric living-donor liver transplantation: De novo or secondary?
✍ Yasumasa Shirouzu; Mureo Kasahara; Yasutsugu Takada; Kaoru Taira; Seisuke Sakamo 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

The development of portopulmonary hypertension (PH) in a patient with end-stage liver disease is related to high cardiac output and hyperdynamic circulation. However, PH following liver transplantation is not fully understood. Of 617 pediatric patients receiving transplants between June 1990 and Mar

Nifedipine versus carvedilol in the trea
Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: Results of a controlled clinical trial
✍ Alessandra Galioto; Andrea Semplicini; Giacomo Zanus; Silvano Fasolato; Antoniet 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB 👁 1 views

The aim of this study was to compare nifedipine and carvedilol in the treatment of de novo arterial hypertension after orthotopic liver transplantation (OLT). The study included 50 patients who developed arterial hypertension after OLT. Twenty-five patients received nifedipine (group A), and 25 rece